Qing Li | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Qing Li | Immunotherapy | Best Researcher Award

Chongqing University, China

Prof. Qing Li is a distinguished researcher and academic whose pioneering contributions in molecular oncology and cancer therapeutics have significantly advanced the understanding of tumor pathogenesis and targeted treatment strategies. His extensive research focuses on elucidating the intricate signaling pathways involved in cancer progression, drug resistance, and immune evasion, with an emphasis on translating molecular insights into clinical applications. Prof. Li has co-authored and led numerous high-impact studies published in leading international journals, showcasing his commitment to bridging the gap between benchside discovery and bedside therapy.Among his major works, Prof. Li has contributed to groundbreaking research uncovering signaling pathways involved in colorectal cancer pathogenesis and targeted therapy, published in Signal Transduction and Targeted Therapy. His collaborative study in Experimental Hematology & Oncology revealed how the downregulation of pro-surfactant protein B contributes to the recurrence of early-stage non-small cell lung cancer by activating PGK1-mediated Akt signaling. In Oncogene, he provided critical insights into how hypoxia inhibits ferritinophagy-mediated ferroptosis in esophageal squamous cell carcinoma through the USP2-NCOA4 axis, while his work in Drug Resistance Updates explored spatial multi-omics approaches to circumvent drug resistance in gastric cancer, offering valuable directions for improving chemo and immuno-therapeutic responses.Prof. Li’s research also extends to nanomedicine, where he has designed innovative drug delivery systems, such as plumbagin-loaded ZIF-90 nanoparticles, to suppress gastric cancer progression by targeting the YAP1 signaling pathway, a study featured in the Chemical Engineering Journal. His investigations in Advanced Science identified the oncogenic role of SAMD9 in promoting postoperative recurrence of esophageal carcinoma via the MYH9-mediated GSK3β/β-catenin signaling cascade. Furthermore, his contributions to Seminars in Cancer Biology and Molecular Therapy have shed light on epigenetic regulation and immune checkpoint dynamics, particularly emphasizing the prognostic role of PD-L1 P146R in gastric cancer immunotherapy outcomes.Beyond publications, Prof. Qing Li has demonstrated excellence in research leadership through his involvement in special projects aimed at improving scientific and technological innovation capabilities. His funded studies focus on understanding the molecular mechanisms by which PD-L1 mutations influence immune escape and the efficacy of PD-1/PD-L1 inhibitors in gastric cancer. His work continues to shape the future of precision oncology, fostering new therapeutic paradigms that enhance patient survival and transform cancer treatment worldwide.

Profile: Orcid

Featured Publications

Wang, H., Yang, Y., Zhang, J., Chen, W., Dai, J., Li, C., & Li, Q. (2025). Integrating single-cell RNA sequencing and artificial intelligence for multitargeted drug design for combating resistance in liver cancer. NPJ Precision Oncology.

Che, G., Yin, J., Wang, W., Luo, Y., Chen, Y., Yu, X., Wang, H., Liu, X., Chen, Z., Wang, X., et al. (2024). Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics. Drug Resistance Updates, 101080.

Song, J., Zhang, J., Shi, Y., Gao, Q., Chen, H., Ding, X., Zhao, M., Zhu, C., Liang, L., Sun, X., et al. (2024). Hypoxia inhibits ferritinophagy-mediated ferroptosis in esophageal squamous cell carcinoma via the USP2-NCOA4 axis. Oncogene.

Wu, C., Zhang, G., Wang, L., Hu, J., Ju, Z., Tao, H., Li, Q., Li, J., Zhang, W., Sheng, J., et al. (2024). Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma. Oncogene.

Luo, H., Hu, B., Gu, X.-R., Chen, J., Fan, X.-Q., Zhang, W., Wang, R.-T., He, X.-D., Guo, W., Dai, N., et al. (2024). The miR-23a/27a/24-2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer. Molecular Cancer.

Mo, Y., Han, Y., Chen, Y., Fu, C., Li, Q., Liu, Z., & Xiao, M. (2024). ZDHHC20 mediated S-palmitoylation of fatty acid synthase (FASN) promotes hepatocarcinogenesis. Molecular Cancer.

Rulla Tamimi | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Rulla Tamimi | Immunotherapy | Best Researcher Award

Dr. Rulla Tamimi at Weill Cornell Medicine Dept of Healthcar, United States.

Dr. Rulla M. Tamimi is a leading cancer epidemiologist and Professor of Population Health Sciences and Pathology at Weill Cornell Medicine. With over two decades of experience in breast cancer research, her work centers on cancer risk prediction, environmental exposures, and molecular epidemiology. A pioneer in integrating biomarkers and epidemiologic data, she has advanced understanding of breast cancer heterogeneity and disparities. Dr. Tamimi is also a principal investigator for multiple NIH-funded studies and a dedicated educator. She plays a critical role in shaping future public health strategies and improving women’s health through rigorous research and community-engaged science.

Publication Profile 

Scopus

Education

Dr. Tamimi holds a B.S. in Biology from Tufts University (1993), followed by an M.S. (1999) and Sc.D. (2003) in Epidemiology from the Harvard T.H. Chan School of Public Health. Her academic training is rooted in public health, statistical methods, and cancer epidemiology. She received advanced training at Harvard, which set the stage for a prolific research and academic career in molecular and clinical epidemiology. Her education enabled her to translate complex biological mechanisms into population-level cancer prevention strategies, and her leadership has consistently bridged rigorous epidemiological research with patient-focused public health innovation.

Experience

Dr. Tamimi has held prestigious academic positions including Instructor, Assistant Professor, Associate Professor at Harvard Medical School and Harvard T.H. Chan School of Public Health (2003–2020). She currently serves as Professor at Weill Cornell Medicine (2020–Present). With over 20 years in academic medicine, she’s also served as Associate Epidemiologist at Brigham and Women’s Hospital. Dr. Tamimi leads NIH- and NCI-funded multi-institutional projects, mentoring future epidemiologists while advancing cancer research. She has contributed to global education through lectures and program direction across institutions including Boston University, Harvard, and National University of Singapore.

Awards 

Dr. Tamimi has received multiple accolades for her visionary research. She earned the “Good Questions Meet Big Data” Ideation Challenge Award from Harvard Catalyst in 2017 and became a Susan G. Komen Scholar in 2020. Her election to prominent organizations such as the American Association for Cancer Research, Society for Epidemiologic Research, and Cornell Center for Health Equity highlights her influence in the field. These recognitions reflect her leadership in molecular epidemiology, commitment to health equity, and significant contributions to cancer prevention research on both national and global scales.

Research Focus 

Dr. Tamimi’s research explores breast cancer heterogeneity, environmental exposures, and the biological underpinnings of cancer risk. Her projects evaluate how dietary carotenoids, genetic variants, circulating metabolites, and breast tissue markers influence cancer outcomes. She is especially interested in aggressive tumor subtypes, breast cancer in young women, and disparities across racial and socioeconomic lines. Current studies also examine stromal contributions to carcinogenesis and social determinants of health through the SoCa Center. Her work connects molecular biology with epidemiological insights to improve early detection, prevention, and personalized treatment strategies for breast cancer.

Publication Top Notes

  • Regular aspirin use, breast tumor characteristics and long-term breast cancer survival
  • Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts
  • Disparities in adherence to guideline-concordant care and receipt of immunotherapy for Non-Small cell lung cancer in the United States
  • Thromboembolic Events Are Increased After Splenectomy in Postmenopausal Women
  • The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages
  • The impact of reproductive factors on breast tumor and normal-adjacent tissue immune profile from menarche to menopause
  • Associations of alcohol consumption with expression of CD44, CD24, and ALDH1A1 stem cell markers in benign breast biopsy samples
  • Breast cancer prevention by short-term inhibition of TGFβ signaling
  • Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses’ health study
  • A genome-wide association study of mammographic texture variation